Kids get lifeline to keep rare swelling disease at bay
NCT ID NCT07159464
Summary
This program allows children aged 2 to 11 with hereditary angioedema (HAE) to continue receiving a preventive drug called garadacimab after they finish a previous clinical trial. It is for kids who did well on the drug, had few or no swelling attacks, and had no major side effects. The goal is to provide continued access to this preventive treatment when no other suitable options are available.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA (HAE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.